{
    "id": 26690,
    "fullName": "EPHA3 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EPHA3 positive indicates the presence of the EPHA3 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2042,
        "geneSymbol": "EPHA3",
        "terms": [
            "EPHA3",
            "EK4",
            "ETK",
            "ETK1",
            "HEK",
            "HEK4",
            "TYRO4"
        ]
    },
    "variant": "positive",
    "createDate": "07/06/2017",
    "updateDate": "04/24/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11400,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with myelofibrosis and positive for EPHA3 showed clinical improvement when treated with KB004 (PMID: 27736729).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9290,
                    "pubMedId": 27736729,
                    "title": "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27736729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11398,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, four patients with acute myeloid leukemia and positive for EPHA3 demonstrated marrow blast clearance after treatment with KB004 (PMID: 27736729).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9290,
                    "pubMedId": 27736729,
                    "title": "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27736729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2572,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KB004 induced apoptosis in primary human multiple myeloma cells expressing EphA3 in culture (53rd ASH Annual Meeting and Exposition, 2010, abstract #2897).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3318,
                    "pubMedId": null,
                    "title": "A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples",
                    "url": "http://www.bloodjournal.org/content/116/21/2897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11399,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 3/5 patients with myelodysplastic syndrome and positive for EPHA3 demonstrated stable disease for at least 6 months after treatment with KB004 (PMID: 27736729).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 50908,
                "name": "myelodysplastic syndrome",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9290,
                    "pubMedId": 27736729,
                    "title": "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27736729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11401,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with myelodysplastic/myeloproliferative cancer and positive for EPHA3 demonstrated senstivity to KB004, showing clinical improvement (PMID: 27736729).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9290,
                    "pubMedId": 27736729,
                    "title": "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27736729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11481,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KB004 induced apoptosis in Epha3-expressing primary chronic myeloid leukemia cells in culture (Blood, 116(21), 2897).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3318,
                    "pubMedId": null,
                    "title": "A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples",
                    "url": "http://www.bloodjournal.org/content/116/21/2897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27991,
            "profileName": "EPHA3 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}